Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bortezomib + Cyclophosphamide + Rituximab in R/R MCL
NCT00958256Phase 2Completed
- Sponsor
- University of Texas MD Anderson Cancer Center
- Start
- Aug 2009
- Primary completion
- Mar 2014
- Modality
- Small Molecules, Modified Peptides
- Countries
- 1
01
Overview
A Phase 2 trial of bortezomib in mantle cell lymphoma (MCL), sponsored by University of Texas MD Anderson Cancer Center. Started Aug 2009; status: completed.
02
Drugs
bortezomib
03
Conditions
mantle cell lymphoma (MCL)
Beyond the preview
Go deeper on NCT00958256.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00958256.